Claire Bartlett

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Nasal cells as a bronchial cell surrogate for pre-clinical assessment of drug response in cystic fibrosis.

Nasal cells as a bronchial cell surrogate for pre-clinical assessment of drug response in cystic fibrosis.

Journal: Frontiers in pharmacology

Published: June 20, 2025

Relationship between theratyping in nasal epithelial cells and clinical outcomes in people with cystic fibrosis.

Relationship between theratyping in nasal epithelial cells and clinical outcomes in people with cystic fibrosis.

Journal: The European respiratory journal

Published: April 16, 2024

Correlation of Electrophysiological and Fluorescence-Based Measurements of Modulator Efficacy in Nasal Epithelial Cultures Derived from People with Cystic Fibrosis.

Correlation of Electrophysiological and Fluorescence-Based Measurements of Modulator Efficacy in Nasal Epithelial Cultures Derived from People with Cystic Fibrosis.

Journal: Cells

Published: March 03, 2023

Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.

Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: January 06, 2023

Validating organoid-derived human intestinal monolayers for personalized therapy in cystic fibrosis.

Validating organoid-derived human intestinal monolayers for personalized therapy in cystic fibrosis.

Journal: Life science alliance

Published: November 26, 2022

Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease.

Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease.

Journal: NPJ genomic medicine

Published: December 30, 2021

Preclinical Studies of a Rare CF-Causing Mutation in the Second Nucleotide Binding Domain (c.3700A>G) Show Robust Functional Rescue in Primary Nasal Cultures by Novel CFTR Modulators.

Preclinical Studies of a Rare CF-Causing Mutation in the Second Nucleotide Binding Domain (c.3700A>G) Show Robust Functional Rescue in Primary Nasal Cultures by Novel CFTR Modulators.

Journal: Journal of personalized medicine

Published: October 12, 2020

Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator.

Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator.

Journal: The European respiratory journal

Published: April 11, 2020

The CFTR Mutation c.3453G > C (D1152H) Confers an Anion Selectivity Defect in Primary Airway Tissue that Can Be Rescued by Ivacaftor.

The CFTR Mutation c.3453G > C (D1152H) Confers an Anion Selectivity Defect in Primary Airway Tissue that Can Be Rescued by Ivacaftor.

Journal: Journal of personalized medicine

Published: April 09, 2020

Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants.

Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: March 02, 2020

A helper-dependent adenoviral vector rescues CFTR to wild-type functional levels in cystic fibrosis epithelial cells harbouring class I mutations.

A helper-dependent adenoviral vector rescues CFTR to wild-type functional levels in cystic fibrosis epithelial cells harbouring class I mutations.

Journal: The European respiratory journal

Published: February 04, 2020

Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action.

Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: July 18, 2019

Showing 1-12 of 15

Last Updated: 09/26/2026